Literature DB >> 20965954

Multicentric Castleman's disease representing effusion at initial clinical presentation: clinicopathological study of seven cases.

M Kojima1, N Nakamura, N Tsukamoto, A Yokohama, H Itoh, S Kobayashi, M Kashimura, N Masawa, S Nakamura.   

Abstract

We present here seven cases of idiopathic multicentric Castleman's disease (MCD) showing effusion at the initial clinical presentation. This series includes a high proportion of middle-aged and elderly females (5/7). Various autoantibodies were detected in six cases. Anemia (Hb < 10 g/dl) was detected in four cases, leukocytosis (WBC > 10 × 10(9)/l) in three and thrombycytopenia (<100 × 10(9)/l) in five. Positivity for C-reactive protein or elevated erythrocyte sedimentation rate was recorded in all seven cases. Elevated serum IgG level (>2000 mg/dl) was recorded in only three cases. Elevated serum interleukin-6 level was recorded in all four cases examined. At the onset of disease, four cases were associated with idiopathic thrombocytic purpura. During the course of disease, one case each was diagnosed as systemic sclerosis + Sjögren's syndrome (SJS) and SJS. Histologically, five lesions exhibited a mixed type of Castleman's disease, and one case each exhibited a hyaline-vascular type and plasma cell type. The non-neoplastic nature of the B-lymphocytes was demonstrated by immunohistochemistry and polymerase chain reaction. There were no human herpes type-8 virus-positive cells in any of the seven lesions. Good responsiveness to glucocorticoid therapy has been seen in all six cases treated. From a therapeutic perspective, it is important to discriminate this subtype of MCD.

Entities:  

Mesh:

Year:  2010        PMID: 20965954     DOI: 10.1177/0961203310381510

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  8 in total

1.  Lymphoid hyperplasia of the thymus showing Castleman's disease in a patient with myasthenia gravis.

Authors:  Masaru Kojima; Kazuhiko Shimizu; Yuko Kaneko; Nobuhide Masawa; Naoya Nakamura
Journal:  Rheumatol Int       Date:  2011-09-27       Impact factor: 2.631

2.  Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version.

Authors:  Yasufumi Masaki; Hiroshi Kawabata; Kazue Takai; Masaru Kojima; Norifumi Tsukamoto; Yasuhito Ishigaki; Nozomu Kurose; Makoto Ide; Jun Murakami; Kenji Nara; Hiroshi Yamamoto; Yoko Ozawa; Hidekazu Takahashi; Katsuhiro Miura; Tsutomu Miyauchi; Shinichirou Yoshida; Akihito Momoi; Nobuyasu Awano; Soichiro Ikushima; Yasunori Ohta; Natsue Furuta; Shino Fujimoto; Haruka Kawanami; Tomoyuki Sakai; Takafumi Kawanami; Yoshimasa Fujita; Toshihiro Fukushima; Shigeo Nakamura; Tomohiro Kinoshita; Sadao Aoki
Journal:  Int J Hematol       Date:  2016-03-18       Impact factor: 2.490

3.  Atypical presentation of multicentric Castleman disease in a pediatric patient: pleural and pericardial effusion.

Authors:  Alkim Oden Akman; Ozge Basaran; Derya Ozyoruk; Unsal Han; Tulin Sayli; Nilgun Cakar
Journal:  Eur J Pediatr       Date:  2015-11-27       Impact factor: 3.183

4.  Diffuse Large B-cell Lymphoma during Corticosteroid Therapy for TAFRO Syndrome.

Authors:  Eiko Ohya; Minoru Mizutani; Haruna Sakaguchi; Takao Sekine
Journal:  Intern Med       Date:  2016-10-01       Impact factor: 1.271

5.  Idiopathic plasmacytic lymphadenopathy: A conceptual history along with a translation of the original Japanese article published in 1980.

Authors:  Kengo Takeuchi
Journal:  J Clin Exp Hematop       Date:  2022

6.  The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman's disease.

Authors:  Ikuko Kubokawa; Akihiro Yachie; Akira Hayakawa; Satoshi Hirase; Nobuyuki Yamamoto; Takeshi Mori; Tomoko Yanai; Yasuhiro Takeshima; Eiryu Kyo; Goichi Kageyama; Hiroshi Nagai; Keiichiro Uehara; Masaru Kojima; Kazumoto Iijima
Journal:  BMC Pediatr       Date:  2014-06-02       Impact factor: 2.125

7.  Sjögren's syndrome manifesting as clinicopathological features of TAFRO syndrome: A case report.

Authors:  Shino Fujimoto; Hiroshi Kawabata; Nozomu Kurose; Haruka Kawanami-Iwao; Tomoyuki Sakai; Takafumi Kawanami; Yoshimasa Fujita; Toshihiro Fukushima; Yasufumi Masaki
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

8.  Development of severe thrombocytopenia with TAFRO syndrome-like features in a patient with rheumatoid arthritis treated with a Janus kinase inhibitor: A case report.

Authors:  Keiichiro Kadoba; Daisuke Waki; Keisuke Nishimura; Hiroki Mukoyama; Rintaro Saito; Hiroyuki Murabe; Toshihiko Yokota
Journal:  Medicine (Baltimore)       Date:  2020-10-16       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.